Bayer Biological Products Launches Initiative to Aid Kogenate(R) FS Patients
04 August 2004 - 4:01PM
PR Newswire (US)
Bayer Biological Products Launches Initiative to Aid Kogenate(R) FS
Patients Multi-faceted patient assistance initiative developed in
response to community needs RESEARCH TRIANGLE PARK, N.C., Aug. 4
/PRNewswire/ -- Bayer Biological Products (BP) has launched a
patient assistance initiative in the United States for eligible
patients receiving treatment with Kogenate(R) FS (Antihemophilic
Factor [Recombinant], Formulated with Sucrose). The Bayer
Kogenate(R) FS Assure Program (BKAP) is comprised of four
components -- a coupon-based program, patient assistance program,
insurance support program, and HELPline, (800) 288-8374, a service
that will answer questions about BKAP, eligibility, enrollment, and
general reimbursement issues. The Kogenate(R) FS Reliance Program
is designed to help patients continue treatment with Kogenate(R) FS
in the event of a lapse in private health insurance coverage.
Beginning August 1, 2004, for every three months of continuous
Kogenate(R) FS use, eligible patients can receive a coupon
redeemable for one free month of Kogenate(R) FS to cover any gaps
in their private health insurance coverage. Patients must enroll in
the program prior to the insurance gap and must be on Kogenate(R)
FS for a continuous year to redeem coupons. Up to six coupons from
similar programs offered by other manufacturers of recombinant
factor VIII will be accepted, provided a patient enrolls in the
program before Dec. 31, 2004. Patients lacking private insurance
may be eligible to obtain Kogenate(R) FS (Antihemophilic Factor
[Recombinant], Formulated with Sucrose) through the Kogenate(R) FS
Patient Assistance Program, a second component of BKAP. In this
program, patients who are legal U.S. residents, without private
insurance, and who meet household income criteria may receive
short-term assistance to obtain Kogenate(R) FS. The Grant Insurance
Support Program supports Patient Services Incorporated (PSI), a
national non-profit organization. PSI offers a number of services,
including helping patients locate and obtain various health
insurance policies. PSI also offers eligible patients assistance
with the cost of prohibitive insurance premium payments. By
contacting the HELPline, a program analyst will refer callers to
PSI. The final component of BKAP is the Bayer Biological
Reimbursement HELPline. Program analysts specially trained to
assist people living with hemophilia and their families will
provide information and answer questions about Kogenate(R) FS, the
BKAP program, or general reimbursement issues. The HELPline is
available weekdays from 8:30 a.m. to 5:30 p.m. Eastern time, and
can be reached via the toll-free number, (800) 288-8374. Patients,
caregivers, and treaters are encouraged to call for assistance
concerning BKAP eligibility and enrollment. "Bayer BP continually
strives to develop products, technologies, and programs to advance
the state of care for people living with hemophilia and their
caregivers," said Terry Tenbrunsel, vice president, U.S. Sales and
Marketing, Bayer Biological Products Division. "However, we
recognize our products may be inaccessible to some members of the
community we serve. To address that concern, Bayer BP is proud to
announce the Bayer Kogenate(R) FS Assure Program as a continuation
of its industry-leading support for the hemophilia community."
Bayer BP remains steadfast in its commitment to shaping the future
of hemophilia care, particularly in the areas of safety and
convenience that translate into demonstrable improvements in the
lives of patients. Bayer BP expects to launch BIO-SET(R), a new
needleless device that includes a prefilled syringe for the
reconstitution and use of Kogenate(R) FS and KOGENATE(R) Bayer, in
early 2005. Additionally, Bayer BP is introducing EZ- Log, a
handheld electronic diary offering patients a new way to record
home treatments and bleeding episodes, track product supply, and
submit refill requests. BIO-SET(R) is a registered trademark of
Biodome. About Kogenate(R) FS Kogenate(R) FS (Antihemophilic Factor
[Recombinant], Formulated with Sucrose) is a recombinant factor
VIII treatment for hemophilia A that offers a more convenient
administration by utilizing a 2.5 mL diluent, the smallest among
available factor VIII products. Kogenate(R) FS does not use albumin
in its purification or formulation, and includes a
solvent/detergent viral inactivation step, thereby further reducing
the potential risk of viral transmission. Kogenate(R) FS is
manufactured at Bayer BP's state-of-the-art biotechnology facility
in Berkeley, Calif. About Bayer HealthCare AG Bayer HealthCare AG,
a subgroup of Bayer AG with sales of approximately 8.9 billion Euro
in 2003, is one of the world's leading, innovative companies in the
health care and medical products industry. The company combines the
global activities of the divisions Animal Health, Biological
Products, Consumer Care, Diagnostics Professional Testing Systems,
and Diagnostics Self Testing Systems and Pharmaceuticals. 34,600
people are employed by Bayer HealthCare worldwide. Our aim is to
discover and manufacture innovative products that will improve
human and animal health worldwide. Our products enhance well-being
and quality of life by diagnosing, preventing, and treating
disease. Information about Bayer Biological Products Division can
be found at http://www.bayerbiologicals.com/. Forward-looking
statements This news release contains forward-looking statements
based on current assumptions and forecasts made by Bayer Group
management. Various known and unknown risks, uncertainties and
other factors could lead to material differences between the actual
future results, financial situation, development or performance of
the company and the estimates given here. These factors include
those discussed in our public reports filed with the Frankfurt
Stock Exchange and with the U.S. Securities and Exchange Commission
(including our Form 20-F). The company assumes no liability
whatsoever to update these forward-looking statements or to conform
them to future events or developments. DATASOURCE: Bayer Biological
Products CONTACT: Tricia McKernan of Bayer, +1-919-316-6316, fax,
+1-919-316-6673,
Copyright